All News
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
Read Article
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.
Read Article
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
EULAR this year proposed new fertility data, especially in Rheumatoid Arthritis, along with an update of the EULAR points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation.
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 randomised controlled trials in Sjogren's disease (iscalimab, ianalumab, dazodalibep, and sequential therapy belimumab + rituximab). Since many previous studies have shown the discordance between physician assessment and patient’s symptom burden, there is a glimmer of hope with the efficacy signals demonstrated by both iscalimab and dazodalibep in two patient cohorts; a) cohort 1 = high disease activity with variable symptom burden and b) cohort 2 = high symptom burden but low disease activity. EULAR 2024 offered additional updates.
Read Article
New Treatments for Systemic Sclerosis
Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
Read Article
Camels and psoriatic arthritis - a new treatment link
I am a big fan of animals and wildlife. Whenever I can, I try to wander outdoors to look for our friends big and small in the animal kingdom. If it rains, as often it does in the UK, the latest edition of Planet Earth will do. So, I was naturally attracted to the presentation by Professor Iain McInnes from the University of Glasgow, oral presentation OP0195 at #EULAR2024 where the link between camels and psoriatic arthritis was made.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
